DK3648788T3 - Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf - Google Patents

Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf Download PDF

Info

Publication number
DK3648788T3
DK3648788T3 DK18746458.1T DK18746458T DK3648788T3 DK 3648788 T3 DK3648788 T3 DK 3648788T3 DK 18746458 T DK18746458 T DK 18746458T DK 3648788 T3 DK3648788 T3 DK 3648788T3
Authority
DK
Denmark
Prior art keywords
patients
administration
treatment
von willebrand
gastrointestinal bleeding
Prior art date
Application number
DK18746458.1T
Other languages
English (en)
Inventor
Miranda Chapman
Bruce Ewenstein
Bettina Ploder
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3648788T3 publication Critical patent/DK3648788T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18746458.1T 2017-07-07 2018-07-09 Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf DK3648788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (1)

Publication Number Publication Date
DK3648788T3 true DK3648788T3 (da) 2024-08-19

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18746458.1T DK3648788T3 (da) 2017-07-07 2018-07-09 Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf

Country Status (16)

Country Link
US (5) US10632176B2 (da)
EP (2) EP4424366A3 (da)
JP (2) JP7307047B2 (da)
KR (2) KR102921337B1 (da)
CN (1) CN111436193A (da)
AU (2) AU2018298233B2 (da)
BR (1) BR112020000321A2 (da)
CA (1) CA3069295A1 (da)
CO (1) CO2020001322A2 (da)
DK (1) DK3648788T3 (da)
ES (1) ES2986574T3 (da)
FI (1) FI3648788T5 (da)
MX (1) MX2025012580A (da)
PL (1) PL3648788T3 (da)
PT (1) PT3648788T (da)
WO (1) WO2019010497A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2865760T3 (da) 2008-06-24 2018-01-15 Csl Behring Gmbh Faktor VIII, Von Willebrand Faktor eller komplekser deraf med forlænget in vivo halveringstid
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011017414A2 (en) 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf

Also Published As

Publication number Publication date
EP4424366A3 (en) 2024-12-04
KR102921337B1 (ko) 2026-02-02
CN111436193A (zh) 2020-07-21
AU2018298233A1 (en) 2020-01-30
RU2020105682A (ru) 2021-08-10
US20230122958A1 (en) 2023-04-20
ES2986574T3 (es) 2024-11-12
US10905746B2 (en) 2021-02-02
JP7641327B2 (ja) 2025-03-06
FI3648788T5 (fi) 2024-09-09
JP2023123738A (ja) 2023-09-05
KR20200037235A (ko) 2020-04-08
FI3648788T3 (fi) 2024-08-16
PL3648788T3 (pl) 2024-10-07
WO2019010497A1 (en) 2019-01-10
US11529395B2 (en) 2022-12-20
US20210169989A1 (en) 2021-06-10
EP3648788B1 (en) 2024-05-22
US20200206318A1 (en) 2020-07-02
PT3648788T (pt) 2024-08-23
US20240316160A1 (en) 2024-09-26
MX2025012580A (es) 2026-01-07
AU2018298233B2 (en) 2025-04-24
BR112020000321A2 (pt) 2020-07-14
JP7307047B2 (ja) 2023-07-11
EP4424366A2 (en) 2024-09-04
AU2025205392A1 (en) 2025-09-25
CO2020001322A2 (es) 2020-02-18
JP2020526525A (ja) 2020-08-31
RU2020105682A3 (da) 2021-10-15
US12016904B2 (en) 2024-06-25
US10632176B2 (en) 2020-04-28
KR20260037107A (ko) 2026-03-17
EP3648788A1 (en) 2020-05-13
US20190091299A1 (en) 2019-03-28
CA3069295A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
EP3691549C0 (en) BLOOD OCCLUSION OR RESTRICTION SLEEVE
PL3648788T3 (pl) Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf
EP3632222C0 (en) BLOOD LEAD REDUCTION SUIT
EP3731850A4 (en) ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
PL3346995T3 (pl) Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
PL3386531T3 (pl) Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
PL3624831T3 (pl) Rekombinowana ludzka alfa-glukozydaza kwasowa
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3350334T3 (da) Udtryk af rekombinante proteiner i trichoplusia ni pupper
EP3597208A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ATPIF1 FOR THE TREATMENT OF DIABETES
EP3619324A4 (en) RECOMBINATED MODIFIED FIBROBLASTIC GROWTH FACTORS AND THEIR THERAPEUTIC USES
DK3538134T3 (da) Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
EP3912658A4 (en) Needleless syringe
DK3274447T3 (da) Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
MA41782A (fr) Traitement de patients atteints de diabète de type 2
EP3903859A4 (en) NEEDLELESS SYRINGE
DK3648787T3 (da) Behandling af patienter, der har svær von willebrand-sygdom og får foretaget elektiv kirurgi, ved administration af rekombinant vwf
EP3752113C0 (en) SURGICAL GAUZE
DK3574912T3 (da) Sammensætning til behandling af diabetisk sygdom
DK3419628T3 (da) Medikament til behandling af diabetiske fodinfektioner
DK3416677T3 (da) Farmaceutisk sammensætning omfattende rekombinant hgh til behandlingen af væksthormonmangel
EP3919094A4 (en) MEDICAL SYRINGE
EP3746065A4 (en) INTRATUMORAL ADMINISTRATION OF BORTEZOMIB